A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

BACKGROUND: The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic color...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, S H, Kim, T W, Hong, Y S, Han, S-W, Lee, K-H, Kang, H J, Hwang, I G, Lee, J Y, Kim, H S, Kim, S T, Lee, J, Park, J O, Park, S H, Park, Y S, Lim, H Y, Jung, S-H, Kang, W K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815882/
https://www.ncbi.nlm.nih.gov/pubmed/26505681
http://dx.doi.org/10.1038/bjc.2015.371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815882/
https://www.ncbi.nlm.nih.gov/pubmed/26505681
http://dx.doi.org/10.1038/bjc.2015.371

Ejemplares similares